03:38 PM EST - QLT Inc. : which said late Wednesday it plans to sell its U.S. operations and cut about half its workforce, is reporting more bad news. Sales of QLT's Visudyne eye treatment declined by 40.5 percent to US$45.5 million in 2007's fourth quarter, compared with the same quarter in 2006, the Vancouver-based company said Thursday. For the full year, Visudyne sales sank 39 percent to US$214.9 million. QLT Inc.
shares T.QLT are trading off 7 cents at $4.41.
